Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anuh PharmaBOM:506260 -0.75%84 Pretax Margin % is 7.68% as of Mar. 2026, which is 16% below its 10-year median of 9.11. GuruFocus rates BOM:506260 with a GF Score™ of 84/100 and a GF Value™ of ₹105.85 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 961 Drug Manufacturers companies, Anuh Pharma ranks worse than 50.68% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Anuh Pharma's Pre-Tax Income for the
three
months ended in Mar. 2026 was ₹155 Mil. Anuh Pharma's Revenue for the
three
months ended in Mar. 2026 was ₹2,021 Mil. Therefore, Anuh Pharma's pretax margin for the quarter that ended in Mar. 2026 was 7.68%.
The historical rank and industry rank for Anuh Pharma's Pretax Margin % or its related term are showing as below:
BOM:506260'
s Pretax Margin % Range Over the Past 10 Years
Min: 6.24 Med: 9.11 Max: 13.38
Current: 7.03
BOM:506260's Pretax Margin % is ranked worse than 50.68% of 961
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs BOM:506260: 7.03
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Anuh Pharma Pretax Margin % Related Terms
Anuh Pharma Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Anuh Pharma's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:506260 vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Anuh Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anuh Pharma Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anuh Pharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Anuh Pharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anuh Pharma (BOM:506260) has a Pretax Margin % of 7.68% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Anuh Pharma and its competitors. This is 16% below median its historical median of 9.11. Over the past decade, Anuh Pharma's Pretax Margin % has ranged from 6.24 to 13.38. According to the industry distribution chart, Anuh Pharma ranks #487 out of 961 companies in the Drug Manufacturers industry, placing it in the top 50.7%.
Is Anuh Pharma's Pretax Margin % too high?
Anuh Pharma's current Pretax Margin % of 7.68% is 16% below median its 10-year median of 9.11. Over the past 10 years, this metric has ranged from a low of 6.24 to a high of 13.38. The Drug Manufacturers industry median Pretax Margin % is 7.28. Anuh Pharma's value of 7.68% is 5.5% above this industry median. Based on the distribution chart, Anuh Pharma ranks #487 out of 961 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Anuh Pharma has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anuh Pharma's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Anuh Pharma ranks #487 out of 961 companies for Pretax Margin %. This places Anuh Pharma in the lower half of its industry. The industry median Pretax Margin % is 7.28. Anuh Pharma's value of 7.68% is 5.5% above this benchmark. Historically, Anuh Pharma's own Pretax Margin % has ranged from 6.24 to 13.38 over the past decade. While the company's 10-year median is 9.11 vs. the industry median of 7.28, Anuh Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anuh Pharma's current Pretax Margin % of 7.68% is 5.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Anuh Pharma and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anuh Pharma's current Pretax Margin % is 7.68%, which is 16% below median its own 10-year median of 9.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anuh Pharma stock overvalued right now?
Based on GuruFocus' analysis, Anuh Pharma (BOM:506260) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹105.85, compared to a current price of ₹78.98 — trading 25.4% below its estimated fair value. The current Pretax Margin % is 7.68%, which is 16% below median its 10-year median of 9.11 and 5.5% above the Drug Manufacturers industry median of 7.28. Anuh Pharma's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Anuh Pharma (BOM:506260), the current Pretax Margin % is 7.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anuh Pharma (BOM:506260) Overvalued in 2026?
Based on GuruFocus' analysis, Anuh Pharma stock appears to be undervalued.
The current stock price of ₹78.98 is trading 25.4% below its estimated GF Value™ of ₹105.85.
GuruFocus considers Anuh Pharma to be Modestly Undervalued.
Key valuation signals for BOM:506260:
Pretax Margin %: 7.68% (16% below median its 10-year median of 9.11)
GF Value™: ₹105.85 vs. price of ₹78.98 (25.4% below fair value)
Industry Position: 5.5% above the Drug Manufacturers median (#487 of 961)
No single metric tells the full story. See the BOM:506260 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anuh Pharma Ltd is engaged in the business of manufacturing and selling of Bulk drugs and chemicals. Geographically, it derives a majority of revenue from India. Its product categories include macrolides, anti-TB, anti-malarial, anti-bacterial, anti-hypertension, expectorant, quinolones, and others. The company generates revenue from the sale of Branded Prescription drugs, Over-the-Counter (OTC) drugs and Generic Prescription drugs.
84GF Score
Get the complete analysis for BOM:506260
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:506260 has been successfully added to your 
